ALC Stock Forecast & Price Target

Alcon is well positioned to sustain mid-single digit revenue growth or better because its visioncare and surgical franchises both benefit from recurring demand, broad product breadth, and a large installed base of ophthalmic equipment. Recent momentum in 2Q26, including ~7% xFx growth, core EPS of $0.84, and margin outperformance of +340bps gross margin and +190bps operating margin, shows that new product launches are translating into stronger operating leverage despite subdued end-market growth. The $550M acquisition of Neurotech Pharmaceuticals adds ENCELTO, a US-only commercial treatment with a ~$250K implant price, ~200M covered lives, and a management-estimated ~$6B TAM, reinforcing the company’s long-term growth and earnings expansion outlook.

Alcon is viewed negatively because its bear case assumes only flat-to low-single digit revenue growth and minimal operating expense leverage, which would translate into slower EPS growth and limited valuation support. Despite FY26 net sales guidance of $10.927 billion to $11.134 billion and core EPS growth of 12%-15% xFx, the company faces a $40 million-$90 million net tariff headwind, slower margin improvement, and the risk that operating margins stay stuck in the low-20s. Weak uptake of new products, rising competition in IOLs and contact lenses, and possible market-share losses could keep growth below the 6%-8% range and leave shares range-bound.